Oral bisphosphonates improve Bone Mineral Density in adults with cystic fibrosis

Oral bisphosphonates improve Bone Mineral Density in adults with cystic fibrosis

In adults with Cystic Fibrosis (CF) we sought to establish the effect of oral bisphosphonate therapy. Bone densitometry measured by dual energy X-ray absorptiometry (DXA), and clinical patient data, were reviewed retrospectively. Eighty-one patients (median age 27 years) had baseline and follow-up D...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Irish medical journal 2005-10, Vol.98 (9), p.270-273
Hauptverfasser: Cawood, T J, McKenna, M J, Gallagher, C G, Smith, D, Wen, Y C, Gibney, J, Dodd, J D, O'Shea, D
Format: Artikel
Sprache:eng
Schlagworte:
Administration, Oral
Adult
Bone Density - physiology
Bone Density Conservation Agents - therapeutic use
Case-Control Studies
Cystic Fibrosis - physiopathology
Diphosphonates - therapeutic use
Female
Humans
Male
Osteoporosis - drug therapy
Osteoporosis - physiopathology
Retrospective Studies
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:In adults with Cystic Fibrosis (CF) we sought to establish the effect of oral bisphosphonate therapy. Bone densitometry measured by dual energy X-ray absorptiometry (DXA), and clinical patient data, were reviewed retrospectively. Eighty-one patients (median age 27 years) had baseline and follow-up DXA, with an interval of 19.2 +/- 7.1 months. Thirty-six patients were treated with bisphosphonates (alendronate=23 and risedronate=13). Median follow-up Bone Mineral Density in the bisphosphonate group was 3.7% greater at the lumbar spine (95%CI 1.9 to 5.7%, P
ISSN:0332-3102